Dye-sensitized photooxidation of 1-methylindolyl-3-acetic acid
作者:Francisco Amat-Guerri、M.Mar C. López-González、Roberto Martínez-Utrilla
DOI:10.1016/s0040-4039(00)94525-8
日期:1983.1
The structure of the products constituting the complex mixture afforded by the entitled reaction is similar to that proceeding from the N-unmethylated acid and supports the presumed mechanistic analogy with the enzymatic oxidation.
Utilisation de (CH 3 ) 3 SiCN comme reactif d'interceptions des intermediaires peroxydes dans le cas de la photooxygenation de derives de l'indole, du methoxymethylene-2 adamantane et du methyl-1 pyrrole
利用 (CH 3 ) 3 SiCN comme reactif d'interceptions des intermediaires dans le cas de la photooxygenation de衍生的吲哚、二甲氧基亚甲基-2金刚烷和二甲基-1吡咯
The Reaction of Singlet Oxygen with 1,3-Dimethylindole in the Presence of Aldehydes. Formation of 1,2,4-Trioxanes
作者:Charles W. Jefford、Danielle Jaggi、John Boukouvalas、Shigeo Kohmoto、G�rald Bernardinelli
DOI:10.1002/hlca.19840670423
日期:1984.6.20
The dye-sensitized photo-oxygenation of 1,3-dimethylindole in the presence of aldehydes initially generates a zwitterionic peroxide which condenses with the carbonyl function to give the corresponding cis-fused 1,2,4-trioxanes. Acetaldehyde gives a pair of diastereomers, one of whose structures was determined by X-ray analysis (cis,cisisomer), whereas pivaladehyde gives only the cis,cis diastereomer
Quinolone sulphonates having antihypertensive activity
申请人:The Boots Company, PLC
公开号:US04997840A1
公开(公告)日:1991-03-05
Quinolone sulphonates of formula I ##STR1## in which R.sub.1 is lower alkyl; R.sub.2 is lower alkyl; and R.sub.3, R.sub.4 and R.sub.5, which may be the same or different, are hydrogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, halo, halogenated lower alkyl, halogenated lower alkoxy, cyano, phenyl or phenyl substituted by 1 or 2 groups independently selected from lower alkyl, lower alkoxy and halo, have antihypertensive activity. Processes for preparing compounds of formula I and pharmaceutical compositions containing them are described. Compounds of formula I are also indicated for use in the treatment of heart failure and ischaemic heart disease.